Immune Response Modifiers from 3M Available for the Pharmaceutical Industry

Release Date:
Thursday, December 2, 2010 10:00 am CST

Terms:
Company (English)  Product and Brand (English)

Dateline City:
ST. PAUL, Minn.

3M Drug Delivery Systems offers worldwide exclusive licenses

ST. PAUL, Minn.--(BUSINESS WIRE)--3M announces the availability of immune response modifier compounds for nonvaccine use in the pharmaceutical industry. The toll-like receptor (TLR) compounds, that activate through TLR7 and TLR8, show promise for the treatment of conditions including cancer, dermatologic diseases and atopic diseases, such as allergy and asthma.

The immune response modifiers available for license broaden 3M's existing offerings of TLR agonists for use as vaccine adjuvants by adding the option of monotherapy.

"These compounds have the potential to help patients that suffer from a variety of disease states making them a very valuable tool to the pharmaceutical industry" said Mark Tomai, PhD, Director of Vaccine Business Development at 3M Drug Delivery Systems.

For more information on licensing the IRMs, contact Dr. Mark Tomai at matomai@mmm.com or (651) 733-5375.

About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M's inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

About 3M Health Care

3M Health Care, one of 3M's six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery, food safety and health information markets.

3M is a trademark of 3M Company.

Language:
English

Contact:
3M Public Relations
Mary Clemens, 651-733-8806
mckokkinen@mmm.com

Michael Gugala, 612-342-9604
Karwoski & Courage
m.gugala@creativepr.com

Ticker Slug:
Ticker: MMM
Exchange: NYSE

Source URL: https://news.3m.com/press-release/company/immune-response-modifiers-3m-available-pharmaceutical-industry